Santos Ivan, Oliveira Maria Beatriz Prior Pinto, Casas Ana, Lopez Javier Fidalgo, Almeida Hugo
REQUIMTE/ LAQV, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Porto, 4050-313, Portugal.
Mesosystem Investigação & Investimentos by Spinpark, Barco, Guimarães, 4805-017, Portugal.
Curr Drug Discov Technol. 2025;22(3):e060624230799. doi: 10.2174/0115701638305553240529103622.
Cannabinoids are compounds with increasing scientific interest, particularly due to their interaction with the endocannabinoid system via CBR1 and CBR2 receptors. They can interfere with appetite, pain, and sleep or develop mood changes in the individual. Cannabidiol (CBD) is a well-known cannabinoid with potential benefits, including reducing epilepsy seizures, alleviating anxiety and obsessive-compulsive disorder (OCD) symptoms, aiding in Tourette Syndrome (a neurodevelopmental disorder), depression, sleep disorders, and promising in the treatment of cancer, pain relief, and heart health. Although generally safe, CBD can have side effects, including drug metabolism interference, fertility, and liver function. In addition, it can be administered by oral, sublingual, transdermal, or inhalation via each one with different bioavailability. The application of nanotechnology, specifically through colloidal carrier systems, holds promising potential for maximizing CBD's efficacy and pharmacological profile. There are reported CBD extraction methods using ethanol, carbon dioxide, deionised water, and non-polar oils like olive or coconut oil. Green extraction methods have gained popularity due to their higher yields, shorter extraction time, and reduced costs. A specific dose with the desired effects is challenging due to individual factors, with most studies suggesting a range between less than 1 and 50 mg/kg/d. This review aims to explore the principles of CBD-based products development, focusing on extraction methods and purification processes of this cannabinoid for tinctures, topicals, and other pharmaceutical forms, as well as further research to attain the objectives.
大麻素是一类愈发引起科学界关注的化合物,特别是因为它们通过CBR1和CBR2受体与内源性大麻素系统相互作用。它们会干扰食欲、疼痛和睡眠,或使个体出现情绪变化。大麻二酚(CBD)是一种广为人知的大麻素,具有潜在益处,包括减少癫痫发作、缓解焦虑和强迫症(OCD)症状、辅助治疗图雷特综合征(一种神经发育障碍)、抑郁症、睡眠障碍,在癌症治疗、缓解疼痛和心脏健康方面也颇具前景。尽管通常安全,但CBD可能有副作用,包括干扰药物代谢、影响生育能力和肝功能。此外,它可以通过口服、舌下含服、透皮或吸入等方式给药,每种方式的生物利用度不同。纳米技术的应用,特别是通过胶体载体系统,在最大化CBD的功效和药理学特性方面具有广阔的潜力。据报道,CBD的提取方法有使用乙醇、二氧化碳、去离子水以及橄榄油或椰子油等非极性油类。绿色提取方法因其产率更高、提取时间更短和成本降低而受到欢迎。由于个体因素,确定具有预期效果的特定剂量具有挑战性,大多数研究表明剂量范围在小于1至50毫克/千克/天之间。本综述旨在探讨基于CBD的产品开发原则,重点关注该大麻素用于酊剂、外用制剂和其他药物剂型的提取方法和纯化过程,以及为实现这些目标的进一步研究。